ClinicalTrials.gg
Enrolling by invitationNCT07676097SMARTFLOWUpdated Nov 2, 2026

Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study

An observational study in Non-obstructive Coronary Disease and Acute or Chronic Coronary Artery Disease, sponsored by AngioInsight. Enrolling by invitation at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by AngioInsight · Observational

How we know

Updated Nov 2, 2026Now Enrolling by invitationFirst site in United Kingdom+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
620
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Microvascular Angina with a site in United States — 6 open to participants now, 8 under way, 1 of them phase 3. Microvascular Angina · United States.

Started
2026
with 1 other
Observational
10 of 22
4 open now
Registered
21st of 22
by date
Lead sponsor
1 of 22
AngioInsight

Among the 22 studies in Microvascular Angina with a site in United States, this one is one of 2 that started in 2026, is one of 10 observational ones, and was the 21st registered.

Microvascular Angina

111 studies on the registry are indexed under Microvascular Angina; 38 are open to participants now.

Browse Microvascular Angina studies →

Open to participants now

6 of the 22 studies in Microvascular Angina with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Microvascular Angina studies recruiting now, 17 (63%) set no upper age limit and 3 (11%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Microvascular Angina with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to establish the diagnostic performance of the AngioAI+ System (AngioInsight, Inc, USA) for estimating:

  1. Fractional flow reserve (FFR) and
  2. Detection of coronary microvascular disease (CMD)

SMARTFLOW is a prospective, single-arm, observational multicenter study of patients with suspected coronary artery disease (CAD) undergoing clinically indicated invasive coronary angiography with physiological assessment. The study is designed to prospectively enroll patient cohorts and collect data according to their reference procedures (e.g. FFR, CFR measures). A core lab will evaluate performance of the AngioAI+ software retrospectively using the collected SMARTFLOW study data. As such, the investigational AngioAI+ device will not inform clinical decisions amid the study procedure.

Read the detailed description

All patients will undergo clinically indicated invasive coronary angiography with physiological assessment according to standard of care.

Cohort 1: Patients with intermediate lesions (30-90% diameter stenosis) will undergo invasive FFR assessment. In patients with FFR >0.80 (non-flow limiting stenosis), subsequent assessment of the microcirculation with bolus and continuous thermodilution will be performed.

Cohort 2: Patients with non-obstructive (\<30% stenosis) disease will undergo assessment of the microcirculation with bolus and continuous thermodilution.

For patients in Cohort 1 with FFR ≤0.80 undergoing percutaneous coronary interventions (PCI), FFR measurements after PCI will be recommended. Use of intravascular imaging will be strongly encouraged to guide PCI procedures, in accordance with current practice guidelines.

03

Conditions studied

  • Non-obstructive Coronary Disease
  • Acute or Chronic Coronary Artery Disease

Browse trials for

Keywords

  • fractional flow reserve
  • coronary microvascular disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute or chronic coronary artery disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute or chronic coronary syndromes referred for invasive coronary angiography with clinically indicated coronary physiologic assessment. In patients with acute coronary syndromes, the physiological evaluation will be restricted to non-culprit vessels.
  • Patients with intermediate CAD (30-90% visual stenosis) with clinically indicated FFR assessment.
  • Patients with NOCAD (\<30% visual stenosis) with clinically indicated microvascular assessment.

Exclusion criteria

Exclusion Criteria:

  • Patients presenting with ST-elevation
  • Prior myocardial infarction in the target vessel
  • Stent implantation in the target vessel within the last 12 months
  • Previous coronary artery bypass grafting surgery (CABG)
  • Previous heart valve surgery
  • Previous heart transplantation
  • Moderate-to-severe valvular disease
  • (EF) ≤45%
  • Hemodynamic instability or cardiogenic shock

Angiographic Exclusion Criteria

  • Left main stenosis≥50%
  • Chronic total occlusion in the target vessel
  • CTO in a non-target vessel
  • Less than thrombolysis in myocardial infarction (TIMI) 3 flow in the target vessel
  • Target vessel receiving collaterals
  • Inadequate coronary angiographic images
  • Ostial lesions
  • Severe tortuosity
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
620 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Patients with intermediate coronary artery stenosis with clinically indicated invasive FFR assessment

    Procedure: Patients with intermediate coronary artery stenosis with clinically indicated FFR assessment.

  • Cohort 2

    Symptomatic patients with non-obstructive coronary artery disease (NOCAD) with clinical indication for invasive coronary microvascular assessment

    Procedure: Microvascular assessment

Interventions

  • ProcedurePatients with intermediate coronary artery stenosis with clinically indicated FFR assessment.

    Cohort 1. Patients with intermediate coronary artery stenosis (30-90% diameter stenosis) with clinically indicated FFR assessment.

  • ProcedureMicrovascular assessment

    Cohort 2: Patients with non-obstructive (\<30% stenosis) disease will undergo assessment of the microcirculation with bolus and continuous thermodilution.

06

What researchers measure

Primary outcomes

  1. To establish the diagnostic performance of the AngioAI+ System

    1\. Per-vessel diagnostic performance (i.e., sensitivity and specificity) of AngioAI+ FFR for identifying flow-limiting lesions, using measured FFR as the reference standard.

    Time frame: June 2026 to December 2027

  2. To establish the diagnostic performance of AngioAI+ System

    Description: 2. Diagnostic performance (i.e., sensitivity and specificity) of AngioAI+ for detecting CMD in patients with non-obstructive CAD using invasive coronary flow reserve (CFR) derived from continuous thermodilution as reference.

    Time frame: June 2026 to December 2027

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Undecided — Decision regarding IPD sharing will be made in the future.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
Jul 28, 2026was Jun 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 2, 2026
Sites
5 sites added — first site in United Kingdom
Show 5 added (4 United Kingdom, 1 United States)
  • Columbia University Medical Center/ NewYork Presbyterian Hospital · New York, United States
  • Essex Cardiothoracic Centre · Basildon, United Kingdom
  • St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust · London, United Kingdom
  • Royal Brompton Royal Brompton Hospital part of Guy's and St Thomas NHS Foundation Trust · London, United Kingdom
  • Imperial College Healthcare NHS Trust · London, United Kingdom
Nov 2, 2026
Start date
Jun 2026→Jul 28, 2026 (actual)
Nov 2, 2026
Contact
No study contact listed any more: removed g•••@angioinsight.com · •••5004; removed j•••@crf.org
Nov 2, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • Palo Alto Veterans Administration Hospital · Palo Alto, United StatesContact removed C•••@pavir.org · •••2808Contact removed (no phone or email listed)
  • Stanford University · Palo Alto, United StatesContact removed v•••@stanford.edu · •••6299Contact removed (no phone or email listed)
  • Washington Hospital Center · Washington D.C., United StatesContact removed e•••@medstar.net · •••7207Contact removed (no phone or email listed)
  • Minneapolis Heart · Minneapolis, United StatesContact removed B•••@allina.com · •••3852Contact removed (no phone or email listed)
  • Valley Health System · Paramus, United StatesContact removed K•••@valleyhealth.com · •••8453Contact removed (no phone or email listed)
  • New York University · New York, United StatesContact removed M•••@nyulangone.org · •••6436Contact removed (no phone or email listed)
  • Northwell Health · New York, United StatesContact removed V•••@northwell.edu · •••6626Contact removed (no phone or email listed)
  • Christ Hospital · Cincinnati, United StatesContact removed R•••@thechristhospital.com · •••2000Contact removed (no phone or email listed)
  • Ascension Saint Thomas · Nashville, United StatesContact removed a•••@ascension.org · •••3815Contact removed (no phone or email listed)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Not yet recruiting→Enrolling by invitation
    5 sites added — first site in United Kingdom
    Show 5 added (4 United Kingdom, 1 United States)
    • Columbia University Medical Center/ NewYork Presbyterian Hospital · New York, United States
    • Essex Cardiothoracic Centre · Basildon, United Kingdom
    • St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust · London, United Kingdom
    • Royal Brompton Royal Brompton Hospital part of Guy's and St Thomas NHS Foundation Trust · London, United Kingdom
    • Imperial College Healthcare NHS Trust · London, United Kingdom
    Start date Jun 2026→Jul 28, 2026 (now actual)
    Contact No study contact listed any more: removed g•••@angioinsight.com · •••5004; removed j•••@crf.org
    Site contacts Changed at 9 sites. See the sites
    Show 9 sites
    • Palo Alto Veterans Administration Hospital · Palo Alto, United StatesContact removed C•••@pavir.org · •••2808Contact removed (no phone or email listed)
    • Stanford University · Palo Alto, United StatesContact removed v•••@stanford.edu · •••6299Contact removed (no phone or email listed)
    • Washington Hospital Center · Washington D.C., United StatesContact removed e•••@medstar.net · •••7207Contact removed (no phone or email listed)
    • Minneapolis Heart · Minneapolis, United StatesContact removed B•••@allina.com · •••3852Contact removed (no phone or email listed)
    • Valley Health System · Paramus, United StatesContact removed K•••@valleyhealth.com · •••8453Contact removed (no phone or email listed)
    • New York University · New York, United StatesContact removed M•••@nyulangone.org · •••6436Contact removed (no phone or email listed)
    • Northwell Health · New York, United StatesContact removed V•••@northwell.edu · •••6626Contact removed (no phone or email listed)
    • Christ Hospital · Cincinnati, United StatesContact removed R•••@thechristhospital.com · •••2000Contact removed (no phone or email listed)
    • Ascension Saint Thomas · Nashville, United StatesContact removed a•••@ascension.org · •••3815Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07676097
Lead sponsor
AngioInsight
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jul 28, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Carlos Collet, MD, PhD
principal investigator · Cardiovascular Research Foundation; OLV Aalst
Todd C Villines, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion